SLC7A7 and breast cancer: Another cohort (GSE1456) including 159 samples showed that SLC7A7 expression was associated with a worse prognosis in breast cancer (relapse-free survival [RFS]; HR = 2.32, 95% CI 1.05–5.14, P = 0.0375).